Sophie Lanzkron

List of Publications by Citations

153 papers	5,408 citations	38 h-index	72 g-index
160 ext. papers	6,576 ext. citations	4.5 avg, IF	5.5 L-index

#	Paper	IF	Citations
153	Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. *JAMA - Journal of the American Medical Association*, **2014**, 312, 1033-48	27.4	858
152	Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. *Public Health Reports*, **2013**, 128, 110-6	2.5	265
151	A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. *New England Journal of Medicine*, **2018**, 379, 226-235	59.2	212
150	Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. *Blood*, **2011**, 118, 855-64	2.2	179
149	Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. *Annals of Internal Medicine*, **2008**, 148, 939-55	8	173
148	Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. *Pediatrics*, **2008**, 122, 1332-42	7.4	161
147	Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. *Blood*, **2015**, 125, 2656-64	2.2	154
146	Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2011**, 305, 893-902	27.4	151
145	The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. *Haematologica*, **2013**, 98, 464-72	6.6	135
144	The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database. *American Journal of Hematology*, **2010**, 85, 797-9	7.1	128
143	Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. *JAMA - Journal of the American Medical Association*, **2014**, 312, 2115-25	27.4	126
142	Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. *American Journal of Hematology*, **2006**, 81, 927-32	7.1	125
141	A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. *Journal of the National Medical Association*, **2009**, 101, 1022-33	2.3	119
140	Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. *American Journal of Medicine*, **2013**, 126, 443-9	2.4	118
139	The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization. *American Journal of Hematology*, **2009**, 84, 666-70	7.1	99
138	Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. *Circulation*, **2011**, 124, 1452-60	16.7	97
137	Provider Barriers to Hydroxyurea Use in Adults with Sickle Cell Disease: A Survey of the Sickle Cell Disease Adult Provider Network. *Journal of the National Medical Association*, **2008**, 100, 968-974	2.3	93

136	Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 2010-6	15.4	88
135	Do Words Matter? Stigmatizing Language and the Transmission of Bias in the Medical Record. *Journal of General Internal Medicine*, **2018**, 33, 685-691	4	82
134	Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. *PLoS ONE*, **2014**, 9, e99489	3.7	82
133	High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. *American Journal of Hematology*, **2006**, 81, 236-41	7.1	70
132	The impact of race and disease on sickle cell patient wait times in the emergency department. *American Journal of Emergency Medicine*, **2013**, 31, 651-6	2.9	68
131	Perceived discrimination, patient trust, and adherence to medical recommendations among persons with sickle cell disease. *Journal of General Internal Medicine*, **2014**, 29, 1657-62	4	67
130	The association of provider communication with trust among adults with sickle cell disease. *Journal of General Internal Medicine*, **2010**, 25, 543-8	4	61
129	Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease. *JAMA Network Open*, **2019**, 2, e1915374	10.4	60
128	Perceived discrimination in health care is associated with a greater burden of pain in sickle cell disease. *Journal of Pain and Symptom Management*, **2014**, 48, 934-43	4.8	60
127	Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. *Journal of Thrombosis and Thrombolysis*, **2013**, 35, 352-8	5.1	59
126	The excess burden of stroke in hospitalized adults with sickle cell disease. *American Journal of Hematology*, **2009**, 84, 548-52	7.1	57
125	An Evaluation of Central Sensitization in Patients With Sickle Cell Disease. *Journal of Pain*, **2016**, 17, 617-27	3.7	55
124	The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease. *Expert Review of Hematology*, **2011**, 4, 597-606	2.8	51
123	Vasculopathy, inflammation, and blood flow in leg ulcers of patients with sickle cell anemia. *American Journal of Hematology*, **2014**, 89, 1-6	7.1	49
122	Chronic Opioid Therapy and Central Sensitization in Sickle Cell Disease. *American Journal of Preventive Medicine*, **2016**, 51, S69-77	6.1	49
121	A video-intervention to improve clinician attitudes toward patients with sickle cell disease: the results of a randomized experiment. *Journal of General Internal Medicine*, **2011**, 26, 518-23	4	48
120	Ex-vivo expansion of bone marrow progenitor cells for hematopoietic reconstitution following high-dose chemotherapy for breast cancer. *Experimental Hematology*, **1999**, 27, 615-23	3.1	47
119	American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. *Blood Advances*, **2019**, 3, 3867-3897	7.8	41

118	Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. *Journal of the National Medical Association*, **2008**, 100, 968-73	2.3	40
117	The Measure of Sickle Cell Stigma: Initial findings from the Improving Patient Outcomes through Respect and Trust study. *Journal of Health Psychology*, **2016**, 21, 808-20	3.1	39
116	Quantitative sensory testing and pain-evoked cytokine reactivity: comparison of patients with sickle cell disease to healthy matched controls. *Pain*, **2016**, 157, 949-956	8	38
115	Health care provider attitudes toward patients with acute vaso-occlusive crisis due to sickle cell disease: development of a scale. *Patient Education and Counseling*, **2009**, 76, 272-8	3.1	38
114	Problematic hospital experiences among adult patients with sickle cell disease. *Journal of Health Care for the Poor and Underserved*, **2010**, 21, 1114-23	1.4	38
113	Prediction of onset and course of high hospital utilization in sickle cell disease. *Journal of Hospital Medicine*, **2011**, 6, 248-55	2.7	37
112	Comparison of US Federal and Foundation Funding of Research for Sickle Cell Disease and Cystic Fibrosis and Factors Associated With Research Productivity. *JAMA Network Open*, **2020**, 3, e201737	10.4	37
111	Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. *American Journal of Hematology*, **2011**, 86, 85-7	7.1	36
110	Hospital self-discharge among adults with sickle-cell disease (SCD): associations with trust and interpersonal experiences with care. *Journal of Hospital Medicine*, **2010**, 5, 289-94	2.7	36
109	The association between sickle cell disease and dental caries in African Americans. *Special Care in Dentistry*, **2006**, 26, 95-100	1.7	33
108	An unequal burden: poor patient-provider communication and sickle cell disease. *Patient Education and Counseling*, **2014**, 96, 159-64	3.1	30
107	Impact of a dedicated infusion clinic for acute management of adults with sickle cell pain crisis. *American Journal of Hematology*, **2015**, 90, 376-80	7.1	29
106	Daily Opioid Use Fluctuates as a Function of Pain, Catastrophizing, and Affect in Patients With Sickle Cell Disease: An Electronic Daily Diary Analysis. *Journal of Pain*, **2018**, 19, 46-56	5.2	28
105	Religious coping and hospital admissions among adults with sickle cell disease. *Journal of Behavioral Medicine*, **2011**, 34, 120-7	3.6	28
104	Multiple Levels of Suffering: Discrimination in Health-Care Settings is Associated With Enhanced Laboratory Pain Sensitivity in Sickle Cell Disease. *Clinical Journal of Pain*, **2016**, 32, 1076-1085	3.5	27
103	Polymerized human Hb use in acute chest syndrome: a case report. *Transfusion*, **2002**, 42, 1422-7	2.9	27
102	A preliminary study of psychiatric, familial, and medical characteristics of high-utilizing sickle cell disease patients. *Clinical Journal of Pain*, **2013**, 29, 317-23	3.5	26
101	Homing of long-term and short-term engrafting cells in vivo. *Annals of the New York Academy of Sciences*, **1999**, 872, 48-54; discussion 54-6	6.5	24

100	Baby on board: what you need to know about pregnancy in the hemoglobinopathies. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 208-214	3.1	22
99	Increased acute care utilization in a prospective cohort of adults with sickle cell disease. *Blood Advances*, **2018**, 2, 2412-2417	7.8	22
98	Disease-Related, Nondisease-Related, and Situational Catastrophizing in Sickle Cell Disease and Its Relationship With Pain. *Journal of Pain*, **2016**, 17, 1227-1236	5.2	20
97	Examining the effectiveness of hydroxyurea in people with sickle cell disease. *Journal of Health Care for the Poor and Underserved*, **2010**, 21, 277-86	1.4	19
96	Risk factors for venous thromboembolism in adults with hemoglobin SC or S(+) thalassemia genotypes. *Thrombosis Research*, **2016**, 141, 35-8	8.2	18
95	Primary Care ProvidersRComfort Levels in Caring for Patients with Sickle Cell Disease. *Southern Medical Journal*, **2015**, 108, 531-6	0.6	17
94	National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017. *Pharmacoepidemiology and Drug Safety*, **2019**, 28, 1246-1250	2.6	16
93	Attitudes toward clinical trials among patients with sickle cell disease. *Clinical Trials*, **2014**, 11, 275-283	2.2	15
92	Provider Barriers to Hydroxyurea Use in Adults with Sickle Cell Disease: A Survey of the Sickle Cell Disease Adult Provider Network. *Journal of the National Medical Association*, **2008**, 100, 968	2.3	15
91	Graft failure in a patient with systemic lupus erythematosus (SLE) treated with high-dose immunosuppression and autologous stem cell rescue. *Bone Marrow Transplantation*, **2001**, 27, 221-4	4.4	15
90	Improving Emergency ProvidersRAttitudes Toward Sickle Cell Patients in Pain. *Journal of Pain and Symptom Management*, **2016**, 51, 628-32.e3	4.8	15
89	Risks associated with fertility preservation for women with sickle cell anemia. *Fertility and Sterility*, **2018**, 110, 720-731	4.8	15
88	The Association between Educational Attainment and Patterns of Emergency Department Utilization among Adults with Sickle Cell Disease. *International Journal of Behavioral Medicine*, **2016**, 23, 300-309	2.6	14
87	Predictors of acute care utilization and acute pain treatment outcomes in adults with sickle cell disease: The role of non-hematologic characteristics and baseline chronic opioid dose. *American Journal of Hematology*, **2018**, 93, 1127-1135	7.1	14
86	A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis. *Medicine (United States)*, **2018**, 97, e11579	1.8	13
85	Baby on board: what you need to know about pregnancy in the hemoglobinopathies. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 208-14	3.1	13
84	Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. *Blood Advances*, **2020**, 4, 3804-3813	7.8	12
83	Clinical and Ophthalmic Factors Associated With the Severity of Sickle Cell Retinopathy. *American Journal of Ophthalmology*, **2019**, 197, 105-113	4.9	12

82	Patent foramen ovale in patients with sickle cell disease and stroke: case presentations and review of the literature. *Case Reports in Hematology*, **2013**, 2013, 516705	0.7	11
81	2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. *Blood Advances*, **2019**, 3, 3945-3950	7.8	11
80	Sickle Cell Disease. *Annals of Internal Medicine*, **2021**, 174, ITC1-ITC16	8	11
79	Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. *Journal of Clinical and Translational Science*, **2018**, 2, 334-342	0.4	11
78	The Association of Clinician Characteristics with their Attitudes Toward Patients with Sickle Cell Disease: Secondary Analyses of a Randomized Controlled Trial. *Journal of the National Medical Association*, **2015**, 107, 89-96	2.3	9
77	Quality improvement process in a sickle cell infusion center. *American Journal of Medicine*, **2015**, 128, 541-4	2.4	8
76	Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. *British Journal of Haematology*, **2020**, 191, 880-887	4.5	8
75	Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease. *Clinical Infectious Diseases*, **2017**, 65, 864-866	11.6	7
74	Evaluation of a train-the-trainer workshop on sickle cell disease for ED providers. *Journal of Emergency Nursing*, **2013**, 39, 539-46	1.3	7
73	Self-perceived loss of control and untreated dental decay in African American adults with and without sickle cell disease. *Journal of Health Care for the Poor and Underserved*, **2006**, 17, 641-51	1.4	7
72	The five key things you need to know to manage adult patients with sickle cell disease. *Hematology American Society of Hematology Education Program*, **2015**, 2015, 420-5	3.1	6
71	GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease. *Blood*, **2013**, 122, 776-776	2.2	6
70	Overcoming challenges of venous thromboembolism in sickle cell disease treatment. *Expert Review of Hematology*, **2019**, 12, 173-182	2.8	6
69	Metabolic syndrome among adults living with sickle cell disease. *Blood Cells, Molecules, and Diseases*, **2019**, 74, 25-29	2.1	6
68	Sickle Cell Disease Mortality in the United States: Age at Death and Contributing Causes.. *Blood*, **2007**, 110, 81-81	2.2	5
67	Screening for Neurocognitive Dysfunction in an Adult Population with Sickle Cell Disease. *Blood*, **2014**, 124, 2717-2717	2.2	5
66	Symptomatic Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization by Patients with SCD. *Southern Medical Journal*, **2016**, 109, 519-24	0.6	5
65	The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study. *Journal of Managed Care & Specialty Pharmacy*, **2020**, 26, 1121-1129	1.9	5

64	Challenges in the management of the transgender patient with sickle cell disease. *American Journal of Hematology*, **2018**, 93, E360-E362	7.1	4
63	Quality Metrics and Health Care Utilization for Adult Patients with Sickle Cell Disease. *Journal of the National Medical Association*, **2019**, 111, 54-61	2.3	4
62	Time to recognize an overlooked trait. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 385-6	12.7	4
61	Utility of the Montreal Cognitive Assessment as a Screening Test for Neurocognitive Dysfunction in Adults with Sickle Cell Disease. *Southern Medical Journal*, **2016**, 109, 560-5	0.6	4
60	Need for Specialized Centers to Provide Acute Care to Adults with Sickle Cell Disease. *Southern Medical Journal*, **2016**, 109, 566-7	0.6	3
59	Innovations in Targeted Anti-Adhesion Treatment for Sickle Cell Disease. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 140-146	6.1	3
58	Effect of Free Dental Services on Individuals with Sickle Cell Disease. *Southern Medical Journal*, **2016**, 109, 576-8	0.6	3
57	Patent foramen ovale in adults with sickle cell disease and stroke. *American Journal of Hematology*, **2016**, 91, E358-60	7.1	3
56	Negative studies shape the state of sickle trait. *Blood*, **2017**, 129, 661-662	2.2	2
55	Look into my eyes: An unusual first presentation of sickle cell disease. *American Journal of Hematology*, **2017**, 92, 968-971	7.1	2
54	Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine. *Blood*, **2018**, 132, 856-856	2.2	2
53	Societal Costs of Sickle Cell Disease in the United States. *Blood*, **2018**, 132, 4706-4706	2.2	2
52	Do Sickle Cell Patients Wait Longer to See Physicians in the Emergency Department?. *Blood*, **2011**, 118, 2070-2070	2.2	2
51	Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease. *Blood*, **2013**, 122, 775-775	2.2	2
50	Improving Inpatient Care for Individuals with Sickle Cell Disease Using the Project ECHO Model. *Southern Medical Journal*, **2016**, 109, 568-9	0.6	2
49	Marijuana use and health behaviors in a US clinic sample of patients with sickle cell disease. *PLoS ONE*, **2020**, 15, e0235192	3.7	2
48	Preliminary evidence that hydroxyurea is associated with attenuated peripheral sensitization in adults with sickle cell disease. *Pain Reports*, **2019**, 4, e724	3.5	2
47	Mortality and Access to Kidney Transplantation in Patients with Sickle Cell Disease-Associated Kidney Failure. *Clinical Journal of the American Society of Nephrology: CJASN*, **2021**, 16, 407-414	6.9	2

46	Treatment of Acute Pain in Adults With Sickle Cell Disease in an Infusion Center Versus the Emergency Department : A Multicenter Prospective Cohort Study. *Annals of Internal Medicine*, **2021**, 174, 1207-1213	8	2
45	The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease. *Journal of Racial and Ethnic Health Disparities*, **2019**, 6, 1233-1243	3.5	1
44	Practice guideline for pulmonary hypertension in sickle cell: direct evidence needed before universal adoption. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 190, 237-8	10.2	1
43	Liver Transplant in Hemoglobin SC Disease and Autoimmune Hepatitis: A Case Report.. *Experimental and Clinical Transplantation*, **2022**,	0.8	1
42	GRNDaD: big data and sickle cell disease.. *Blood Advances*, **2022**, 6, 1088	7.8	1
41	Predictors of In-Hospital Mortality and Charges in Sickle Cell Disease: Results from the California Discharge Databases 1998–2005.. *Blood*, **2007**, 110, 432-432	2.2	1
40	Trends In the Hospital Treatment of Sickle Cell Disease-Related Priapism In the United States: 1998 to 2007,. *Blood*, **2011**, 118, 4195-4195	2.2	1
39	Cost Benefit Analysis Of a Sickle Cell Infusion Center For The Treatment Of Vaso-Occlusive Crises. *Blood*, **2013**, 122, 1697-1697	2.2	1
38	Perceived Discrimination In Health Care Is Associated With Daily Chronic Pain In Sickle Cell Disease. *Blood*, **2013**, 122, 5577-5577	2.2	1
37	Successful Use of Pegylated Carboxyhemoglobin Bovine As an Emergency Treatment for Severe Anemia in a Patient with Sickle Cell Disease and Hyperhemolysis: A Case Report. *Blood*, **2014**, 124, 4928-4928	2.2	1
36	Metabolic Syndrome Risk Among Adults Living with Sickle Cell Disease. *Blood*, **2015**, 126, 3405-3405	2.2	1
35	Acute Care Utilization Is More Common in Patients with Sickle Cell Disease Who Have Chronic Complications and Chronic Pain: A Preliminary Report from the Escaped Trial. *Blood*, **2016**, 128, 2490-2490	2.2	1
34	Acceptable, hopeful, and useful: development and mixed-method evaluation of an educational tool about reproductive options for people with sickle cell disease or trait. *Journal of Assisted Reproduction and Genetics*, **2021**, 39, 183	3.4	1
33	Hospitalization Rates in Patients with Sickle Cell Disease (SCD) in the State of Maryland (MD): No Change Since Approval of Hydroxyurea (HU).. *Blood*, **2004**, 104, 107-107	2.2	1
32	A Five Fold Decrease in Admissions for Uncomplicated Vaso-Occlusive Crisis and Other Benefits from Care in Infusion Clinics: Results from the Escaped Trial. *Blood*, **2018**, 132, 853-853	2.2	1
31	Non-Cardiopulmonary Factors Affecting the Six-Minute Walk Distance in Patients with Sickle Cell Disease: Results From the Walk-PHaSST Study. *Blood*, **2011**, 118, 1074-1074	2.2	1
30	Psychosocial and Clinical Risk Factors Associated with Substance Use in Observational Cohort of Patients with Sickle Cell Disease. *Substance Use and Misuse*, **2020**, 55, 2205-2212	2.2	1
29	Women with sickle cell disease report low knowledge and use of long acting reversible contraception. *Journal of the National Medical Association*, **2021**, 113, 552-559	2.3	1

28	A community-centered approach to sickle cell disease and clinical trial participation: an evaluation of perceptions, facilitators, and barriers. *Blood Advances*, **2021**, 5, 5323-5331	7.8	1
27	Swaying sickle cell research forward in support of patient reported outcomes. *American Journal of Hematology*, **2021**, 96, 402-403	7.1	1
26	Modifiable Cardiovascular Risk Factors in Adults with Sickle Cell Disease. *Blood*, **2018**, 132, 1088-1088	2.2	0
25	Gaps in the diagnosis and management of iron overload in sickle cell disease: a Real-world Report from the GRNDaD registry. *British Journal of Haematology*, **2021**, 195, e157-e160	4.5	0
24	Pregnancy in Subjects with Hemoglobinopathies: Precautions and Management **2016**, 661-668		
23	The reply. *American Journal of Medicine*, **2013**, 126, e15	2.4	
22	Experience of Respect and Pain Management among Adult Patients with Sickle Cell Disease during Vaso-Occlusive Crisis.. *Blood*, **2006**, 108, 3341-3341	2.2	
21	Risk Factors for Primary Hemorrhagic Stroke in Adults with Sickle Cell Disease.. *Blood*, **2007**, 110, 3809-3809	2.2	
20	Documenting the Effectiveness of Hydroxyurea (HU) To Treat Sickle Cell Disease (SCD) in the Community Setting.. *Blood*, **2007**, 110, 956-956	2.2	
19	Developmental Outcomes of Children Exposed to Maternal Sickle Cell Disease (SCD). *Blood*, **2017**, 130, 983-983	2.2	
18	Iron Overload Is Under-Recognized and Under-Treated in SCD: A Report from the Grndad Registry. *Blood*, **2018**, 132, 158-158	2.2	
17	Patient Satisfaction of Care in the Treatment of Vaso-Occlusive Crises: A Comparison of Emergency Department and Infusion Centers in the Escaped Study. *Blood*, **2018**, 132, 314-314	2.2	
16	Patent Foramen Ovale in Adult Patients with Sickle Cell Disease and Stroke. *Blood*, **2014**, 124, 4084-4084	2.2	
15	Essential Thrombocytosis: Redefinition in the Genomic Era. *Blood*, **2014**, 124, 3205-3205	2.2	
14	Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization By Patients with Sickle Cell Disease. *Blood*, **2014**, 124, 2709-2709	2.2	
13	An Analysis of VTE Prophylaxis Practice in Oncology Patients after Implementation of a Standardized Mandatory Computerized Clinical Decision Support Tool. *Blood*, **2014**, 124, 4859-4859	2.2	
12	Hospitalization for Acute Pain in Sickle Cell Disease: Changes in Clinical Parameters and Factors Predicting Hospital Discharge and Re-Admission. *Blood*, **2016**, 128, 3662-3662	2.2	
11	NT-Probnp as a Marker of Cardiopulmonary Compromise and Exercise Limitation In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. *Blood*, **2010**, 116, 1639-1639	2.2	

10	Predictors of Six-Minute Walk Distance In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. *Blood*, **2010**, 116, 947-947	2.2
9	Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study. *Blood*, **2010**, 116, 2658-2658	2.2
8	Trends In Mortality Rates and Age of Death In Sickle Cell Disease (SCD): 1979–2005. *Blood*, **2010**, 116, 736-736	2.2
7	Cigarette Smoking Is An Independent Predictor of Chronic Pain In Sickle Cell Patients: Results From the Walk-PHaSST Study. *Blood*, **2010**, 116, 4804-4804	2.2
6	Describing Adherence to Recommended Preventative Care Behaviors Among Adults with Sickle Cell Disease. *Blood*, **2012**, 120, 2058-2058	2.2
5	Polycythemia Vera: Redefinition in the Genomic Era. *Blood*, **2012**, 120, 1754-1754	2.2
4	Higher Baseline Hemoglobin and Splenectomy Are Risk Factors for Venous Thromboembolism in Adults with Sickle Cell Variant Genotypes. *Blood*, **2012**, 120, 3243-3243	2.2
3	Venous Thromboembolism Incidence In The Cooperative Study Of Sickle Cell Disease: The Untold Story. *Blood*, **2013**, 122, 2214-2214	2.2
2	Low rates of transfusion-transmitted infection screening in chronically transfused adults with sickle cell disease. *Transfusion*, **2021**, 61, 2421-2429	2.9
1	Health Care Utilization by Adolescent/Young Adult Patients With Sickle Cell Disease in Delaware.. *Cureus*, **2022**, 14, e22700	1.2